Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as
Scientists published a study showing that Coya's new medicine combo works better together than each part alone for reducing body swelling. When a company shares good science results, it's a sign their medicine might be heading toward helping real patients someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.